TRCT
CURX

Tower Research Capital (TRC)’s Curanex Pharmaceuticals CURX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265 Buy
+1,000
New +$364 ﹤0.01% 5082

Other funds holding CURX

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s CURX Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Curanex Pharmaceuticals (CURX) in Q2 2026: 1,000 shares worth $265. The stake represents ﹤0.01% of the portfolio and ranks #5082 among its holdings.

6 funds tracked by Wall St. Rank hold CURX as of Q2 2026.

  • Tower Research Capital (TRC) held 1,000 shares of Curanex Pharmaceuticals worth $265 as of Q2 2026.
  • Curanex Pharmaceuticals was a new Tower Research Capital (TRC) position in Q2 2026.
  • Curanex Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #5082 holding.
  • 6 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.